Rotavirus
Non-enveloped triple-layered icosahedral virus with 11 dsRNA genome segments encoding 6 structural (VP1–VP4, VP6, VP7) and 6 non-structural (NSP1–NSP6) proteins. VP8* tip of the VP4 spike mediates HBGA/glycan attachment; VP5* drives endosomal membrane penetration. NSP4 acts as a viral enterotoxin — secreted by infected enterocytes, it elevates intracellular calcium in adjacent uninfected cells via phospholipase C-independent pathways, activating CFTR-mediated chloride secretion and producing secretory diarrhea before significant villous destruction. NSP1 broadly suppresses innate immunity by targeting IRF3, IRF5, IRF7, and β-TrCP for proteasomal degradation. Vaccine-preventable: Rotarix and RotaTeq are highly effective in high-income settings.
Classification & Structure
| Family / genus | Reoviridae / Rotavirus; species A–J; Rotavirus A (RVA) causes virtually all human disease; binary classification by outer capsid serotype: VP7 G-type and VP4 P-type (e.g., G1P[8]) |
| Genome | 11 dsRNA segments; ~18.5 kb total; each segment encodes 1 protein except segment 11 (encodes NSP5 + NSP6 from two ORFs) |
| Outer capsid | VP7 (58 kDa glycoprotein, G-type serotype antigen) + VP4 spike (P-type; trypsin-cleaved to VP8* + VP5*); VP8* HBGA/sialoglycan binding; VP5* membrane penetration; together determine neutralization serotype |
| Middle layer | VP6 (45 kDa) — most abundant structural protein; species/group antigen (A–J); not exposed on intact virion; target of protective IgA acting within the transcytosis pathway |
| Core | VP2 (structural scaffold), VP1 (RdRp; transcribes all 11 segments simultaneously), VP3 (capping enzyme + 2'-5'-phosphodiesterase — degrades 2-5A to block RNase L) |
| NSP4 — enterotoxin | Non-structural transmembrane glycoprotein; first viral enterotoxin discovered; secreted by infected enterocytes; binds adjacent uninfected cells via integrin α1β1; mobilizes intracellular Ca2+ via PLC-independent pathway → activates CFTR and Ca2+-dependent Cl⁻ channels → secretory diarrhea preceding cell death; also activates enteroendocrine cells (5-HT, substance P) via enteric nervous system → vomiting reflex via vagal afferents |
| NSP1 — IFN antagonist | RING finger domain; targets IRF3, IRF5, IRF7 (IFN transcription factors) and β-TrCP (activator of NF-κB and IFN-induction) for proteasomal degradation; broadly suppresses innate antiviral gene expression; strain-specific variation in potency |
| Dominant strains | G1P[8], G2P[4], G3P[8], G4P[8], G9P[8] — >80% of global cases; G3P[8] increasing in prevalence post-vaccine introduction in some settings |
Infection Mechanism
1 · Sequential cell attachment — a multi-step process
Rotavirus attachment to villus tip enterocytes is an ordered cascade. VP8* (tip of the VP4 spike) first engages histo-blood group antigens (HBGAs) or sialylated glycolipids on the apical surface: P[8] strains bind Lewis b/H type 1; P[4] binds Lewis x/Lewis b; P[6] binds A antigen. This HBGA interaction is followed by engagement of post-attachment co-receptors: Hsc70 (heat shock cognate 70) binds VP5*, and integrins α2β1, αvβ3, and αxβ2 mediate tight virus-cell contact and trigger endocytic uptake.
2 · Endosomal uncoating and genome delivery
Rotavirus enters via receptor-mediated endocytosis. Endosomal calcium chelation (by NPC1L1 or other transporters) causes outer capsid disassembly — VP7 and VP4 are shed — generating a transcriptionally active double-layered particle (DLP). VP5* undergoes class II fusion protein-like conformational rearrangement to penetrate the endosomal membrane and deliver the DLP into the cytoplasm. Within the DLP, VP1 RdRp simultaneously transcribes all 11 genome segments into capped, non-polyadenylated positive-sense mRNAs. The VP3 2'-5'-PDE activity cleaves 2-5A oligoadenylates generated downstream of OAS pathway activation, blocking RNase L-mediated mRNA degradation.
3 · Replication in viroplasms and assembly
Viral replication and assembly occur in cytoplasmic viroplasms — dense inclusions formed by NSP2 and NSP5 that concentrate VP1, VP2, VP3, and VP6 around packaging positive-sense RNA. VP1 dsRNA synthesis produces the dsRNA genome within assembling cores. New triple-layered particles bud through the endoplasmic reticulum membrane, where VP7 and VP4 are acquired from ER-resident pools. Viroplasms sequester dsRNA intermediates from cytosolic MDA5/RIG-I detection, limiting innate immune sensing during active replication.
4 · NSP4 enterotoxin — two-phase diarrhea mechanism
Phase 1 (early secretory, begins within hours): NSP4 secreted by infected enterocytes acts on adjacent uninfected cells to elevate intracellular Ca2+ via a phospholipase C-independent mechanism. Elevated Ca2+ activates CFTR and calcium-dependent Cl⁻ channels → active chloride secretion → osmotic water efflux into gut lumen → watery diarrhea before any structural damage is visible. NSP4 simultaneously activates enteroendocrine cells to release serotonin (5-HT), activating the enteric nervous system and vagal afferents to trigger the vomiting reflex. Phase 2 (late malabsorptive, days 1–3): Villous tip cell lysis reduces SGLT1 sodium-glucose cotransporter activity and brush-border enzyme (lactase, sucrase-isomaltase) levels → osmotic diarrhea from carbohydrate malabsorption. Both phases compound to produce the profound dehydration seen in severe infant disease.
5 · Innate immune evasion — NSP1 and VP3
NSP1 RING finger domain targets host IRF3, IRF5, and IRF7 — the primary transcription factors for IFN-β and IFN-α4 induction — as well as β-TrCP (an E3 ligase subunit required for both IKKβ-activated NF-κB and IFN-related signaling) for proteasomal degradation. This broadly suppresses the innate antiviral transcriptional program during early infection. VP3 possesses 2'-5'-phosphodiesterase (PDE) activity: it degrades 2-5A oligoadenylate second messengers produced by the OAS1/2/3 pathway, blocking RNase L activation and preventing the RNA degradation response to dsRNA sensing.
Host Immune Response
Disease Spectrum
| Presentation | Typical Host | Key Features |
|---|---|---|
| Asymptomatic infection | Neonates; re-exposed adults | Common; neonatal P[6] strains often non-pathogenic; serological evidence of prior infection universal by age 5; remains a transmission source |
| Mild-to-moderate gastroenteritis | Children 6 months – 2 years | Watery non-bloody diarrhea 3–8 days; vomiting; low-grade fever; ORT sufficient; most common presentation in vaccinated populations |
| Severe dehydrating gastroenteritis | Children 3 months – 2 years (peak); elderly | High-volume watery diarrhea; profound isonatraemic dehydration (weight loss >5%); IV fluid replacement required; most severe with primary (first) infection; accounts for virtually all rotavirus mortality |
| Chronic infection | Immunocompromised: SCID, HIV, HSCT, solid organ transplant | Persistent diarrhea weeks to months; evolving quasi-species in serial stool samples; biliary and hepatic involvement (cholestatic jaundice, transaminase elevation); potential systemic viremia detected in mesenteric macrophages |
| Extraintestinal manifestations | Rare in immunocompetent hosts | Transient afebrile seizures / "benign convulsions with mild gastroenteritis" (CwG) — self-limiting, mechanism unclear; transient hepatitis; intussusception risk marginally elevated with oral live vaccines (pre-licensure RRV-TV, not current vaccines) |
Treatment & Prevention
Oral rehydration therapy (ORT) — cornerstone of treatment
WHO/UNICEF low-osmolarity ORS (sodium 75 mmol/L, glucose 75 mmol/L, potassium 20 mmol/L, citrate 10 mmol/L; osmolarity 245 mOsm/L) exploits SGLT1 co-transporter function in crypt-derived cells that survive rotavirus infection. First-line for mild-to-moderate dehydration. Zinc supplementation (10–20 mg/day for 10–14 days) reduces disease duration and severity in low-income settings (WHO/UNICEF recommendation). IV fluids (Ringer's lactate or 0.9% saline) for severe dehydration or inability to tolerate oral intake.
Rotarix (GSK) — monovalent oral live-attenuated vaccine
Monovalent G1P[8] attenuated human rotavirus strain (89-12); 2-dose oral schedule at 6 and 10 weeks of age. Efficacy: ~85–90% against severe rotavirus gastroenteritis in high-income countries (HIC); ~50–65% in low-income countries (LIC). WHO-recommended for inclusion in all national immunization programmes. Dramatically reduced rotavirus hospitalisations in countries with >80% coverage. No clinically meaningful intussusception risk with current formulation.
RotaTeq (Merck) — pentavalent oral live-attenuated vaccine
Pentavalent human-bovine reassortant vaccine (WC3 bovine backbone with human VP7 G1–G4 and VP4 P[8] genes); 3-dose oral schedule at 2, 4, and 6 months. Efficacy: ~85–98% against severe disease in HIC settings; ~39–63% in LIC. Broader genotype coverage theoretically advantageous for strain diversity but efficacy gap vs monovalent in LMIC similar.
ROTAVAC and RotaSIIL — equity-oriented LMIC vaccines
ROTAVAC (Bharat Biotech): monovalent 116E human-bovine reassortant neonatal strain; 3-dose oral schedule; ~55% efficacy against severe disease in India; lowest cost, locally produced, WHO-prequalified. RotaSIIL (Serum Institute of India): pentavalent bovine-human reassortant; 3-dose; ~67% efficacy; also WHO-prequalified. Both address cold-chain and cost barriers that limit Rotarix/RotaTeq reach in highest-mortality settings. No specific antiviral approved; nitazoxanide shows modest benefit in some trials but is not universally recommended.
Connections
References
- Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020. elsevier.com
- Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 9th ed. Elsevier; 2021. elsevier.com
- Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. Global, regional, and national estimates of rotavirus mortality in children <5 years, 2000-2013. Clin Infect Dis. 2016;62(Suppl 2):S96-S105. doi:10.1093/cid/civ1013 · PubMed 26966244
- Estes MK, Kapikian AZ. Rotaviruses. In: Knipe DM, Howley PM, eds. Fields Virology. 5th ed. Lippincott Williams & Wilkins; 2007:1917-1974.
- Parashar UD, Johnson H, Estes MK, Gentsch JR. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis. 2003;9(5):565-572. doi:10.3201/eid0905.020562 · PubMed 12737740
Contribute to the Pathogen Atlas
This entry covers rotavirus triple-layered capsid biology, NSP4 enterotoxin two-phase diarrhea mechanism, and the global vaccine landscape. Planned expansions: viroplasm liquid-liquid phase condensate biology, P-type HBGA-binding specificity variation, vaccine efficacy gap in LMIC. Every entry follows the same schema: structured frontmatter, peer-reviewed citations, and cross-atlas links.